G92.00 Immune effector cell-associated neurotoxicity syndrome, grade unspecified

Name of the Condition

• Immune effector cell-associated neurotoxicity syndrome, grade unspecified

Summary

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological condition that can occur following treatment with certain immunotherapies, particularly those involving immune effector cells like CAR T-cells. It is characterized by a range of neurologic symptoms resulting from inflammation or toxicity to the central nervous system. The "grade unspecified" designation indicates that the severity of the syndrome has not been classified using a standardized grading system.

Causes

ICANS is caused by the release of inflammatory cytokines and immune-mediated damage to the brain and nervous system, typically triggered by immunotherapy treatments that activate immune cells to target cancer cells. The exact mechanisms involve cytokine release and potential direct neurotoxic effects.

Risk Factors

• Receipt of immunotherapy, especially CAR T-cell therapy or other immune effector cell treatments
• Underlying cancer type and disease burden
• Prior history of neurologic conditions or central nervous system involvement
• Concomitant use of other medications that may affect neurologic function

Symptoms

• Altered mental status or confusion
• Aphasia (difficulty speaking or understanding language)
• Tremors or asterixis (hand flapping)
• Seizures
• Headache
• Dizziness or ataxia (loss of coordination)
• Visual disturbances

Diagnosis

Diagnosis is based on clinical evaluation of neurologic symptoms in the context of recent immunotherapy administration. No specific laboratory test confirms ICANS, but clinicians assess symptom onset, progression, and exclusion of other causes. Grading systems (e.g., ASTCT consensus) may be used to assess severity, though the unspecified grade indicates this was not applied or documented.

Treatment Options

• Supportive care, including monitoring and management of symptoms
• Corticosteroids (e.g., dexamethasone) to reduce inflammation
• Antiseizure medications if seizures occur
• Discontinuation or adjustment of immunotherapy if severe
• Intensive care for severe cases (e.g., airway protection, hemodynamic support)

Prognosis and Follow-Up

Prognosis depends on the severity of symptoms and promptness of treatment. Most patients recover with appropriate management, but severe cases may have prolonged or permanent neurologic effects. Follow-up includes regular neurologic assessments to monitor for resolution or recurrence of symptoms.

Complications

• Prolonged confusion or cognitive impairment
• Seizure disorders
• Cerebral edema (swelling of the brain)
• Respiratory failure requiring mechanical ventilation
• Death in rare, severe cases

Lifestyle & Prevention

• Close monitoring during and after immunotherapy for early symptom detection
• Adherence to prescribed medications and treatment protocols
• Avoidance of other neurotoxic substances (e.g., alcohol) during therapy
• Prompt reporting of new or worsening neurologic symptoms to healthcare providers

When to Seek Professional Help

Seek immediate medical attention if experiencing:

• Sudden confusion, difficulty speaking, or altered consciousness
• Seizures or convulsions
• Severe headache, dizziness, or loss of coordination
• Visual changes or difficulty walking

Tips for Medical Coders

Document the clinical context of immunotherapy administration and the presence of neurologic symptoms consistent with ICANS. Ensure the "grade unspecified" designation is used only when severity grading is not documented or applicable. Code G92.00 is appropriate when the condition is diagnosed without a specified grade. Include details on symptom onset, treatment, and response to support accurate coding and clinical correlation.